Inferior cancer survival for men with localized high-grade prostate cancer but low prostate-specific antigen
AuthorsFankhauser, Christian D
Gonzalez-Feliciano, A. G.
Clarke, Noel W
Stopsack, K. H.
Gerke, T. A.
Preston, M. A.
Mucci, L. A.
AffiliationDepartment of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland;
MetadataShow full item record
CitationFankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, et al. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020.
- The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
- Authors: Maggi M, Cowan JE, Fasulo V, Washington SL 3rd, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR
- Issue date: 2020 Dec
- Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
- Authors: Aizer AA, Chen MH, Hattangadi J, D'Amico AV
- Issue date: 2014 Jan
- Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.
- Authors: Weiner AB, Etzioni R, Eggener SE
- Issue date: 2014 Oct
- Prostate cancer: primary ADT monotherapy not suitable for localized disease.
- Authors: Sartor O, Silberstein J
- Issue date: 2014 Jun
- Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
- Authors: Ang M, Rajcic B, Foreman D, Moretti K, O'Callaghan ME
- Issue date: 2016 Apr